Sofinnova Partners Closes Oversubscribed Fund XI at €650M for Biotech, MedTech
November 19, 2025, 9:32 am
Sofinnova Partners closed Fund XI at €650M. The fund will back early-stage biopharma and MedTech firms. It surpasses its original target. The fund will invest in Europe and North America. Sofinnova targets unmet clinical needs.
Paris-based Sofinnova Partners just closed its Fund XI. The fund reached €650 million. It exceeded its initial target. The money will fuel biopharma and MedTech startups. The focus remains on Europe and North America.
Sofinnova's Fund XI attracted global investors. Sovereign wealth funds participated. Pharmaceutical giants also invested. Insurance firms, foundations, and family offices joined. The British Business Bank committed €30 million. This aligns with the UK's Life Sciences Sector Plan. The oversubscription demonstrates investor faith. They believe in Sofinnova's strategy.
The fund targets early-stage companies. Sofinnova aims to address unmet clinical needs. They seek groundbreaking research with therapeutic potential. Investments will span biopharma and MedTech. The focus is on translating science into impactful solutions. Sofinnova will invest in initial and follow-on rounds.
Founded in 1972, Sofinnova boasts a strong track record. They operate from Paris, London, and Milan. Their portfolio includes over 500 companies. The firm manages over €4 billion in assets. They are known for science-driven investing. They actively build companies.
Other European funding rounds show sector activity. Adcytherix secured €105 million in France. They develop antibody-drug conjugates for cancer. Cellcolabs in Sweden raised €10.3 million. They scale mesenchymal stem cell manufacturing. Arcoris bio in Switzerland closed €6.7 million. They develop biomarker detection technology.
Sofinnova Capital XI is deploying capital now. Investments have already been made. Latent Labs, BioCorteX, and Amolyt are among the recipients.
Sofinnova's team is experienced. Maina Bhaman is a Partner. Anta Gkelou is a Partner. Karl Naegler is a Partner. Antoine Papiernik chairs the company. Henrijette Richter and Graziano Seghezzi are also Partners.
Fund XI gained support globally. Investors came from Europe, North America, Asia, and the Middle East. Many were returning investors. New top-tier investors joined as well.
Antoine Papiernik highlighted the fundraising's importance. He emphasized doubling down on early-stage opportunities. He praised the collaborative, science-driven approach. He is excited to back visionary entrepreneurs. He wants to advance breakthroughs to patients.
Mark Andrews from the British Business Bank commented. He sees Sofinnova as a key life sciences player. Their commitment will boost UK life sciences investment. This will solidify Sofinnova's UK connection.
Christine Hockley addressed the UK market. She emphasized the need for capital. She wants high-potential companies to access funding. Funds with deeper capital pools are needed. They should invest in the UK's growth stage.
The fund solidifies Sofinnova's role. They are a cornerstone investor in early-stage ventures. Total capital raised across Sofinnova reached €1.5 billion recently. Fund XI will accelerate scientific advances. It will drive commercial success. This benefits the next generation of healthcare innovators. Sofinnova will continue supporting early-stage biotech and medtech ventures. They will participate in both initial and follow-on rounds.
"
Sofinnova Partners Secures €650M for Biotech and MedTech Innovation
Paris-based Sofinnova Partners just closed its Fund XI. The fund reached €650 million. It exceeded its initial target. The money will fuel biopharma and MedTech startups. The focus remains on Europe and North America.
Oversubscribed Fund Signals Strong Investor Confidence
Sofinnova's Fund XI attracted global investors. Sovereign wealth funds participated. Pharmaceutical giants also invested. Insurance firms, foundations, and family offices joined. The British Business Bank committed €30 million. This aligns with the UK's Life Sciences Sector Plan. The oversubscription demonstrates investor faith. They believe in Sofinnova's strategy.
Strategic Focus on Early-Stage Innovation
The fund targets early-stage companies. Sofinnova aims to address unmet clinical needs. They seek groundbreaking research with therapeutic potential. Investments will span biopharma and MedTech. The focus is on translating science into impactful solutions. Sofinnova will invest in initial and follow-on rounds.
Sofinnova's Long-Standing Legacy
Founded in 1972, Sofinnova boasts a strong track record. They operate from Paris, London, and Milan. Their portfolio includes over 500 companies. The firm manages over €4 billion in assets. They are known for science-driven investing. They actively build companies.
Recent European Funding Highlights
Other European funding rounds show sector activity. Adcytherix secured €105 million in France. They develop antibody-drug conjugates for cancer. Cellcolabs in Sweden raised €10.3 million. They scale mesenchymal stem cell manufacturing. Arcoris bio in Switzerland closed €6.7 million. They develop biomarker detection technology.
Fund XI Already Active
Sofinnova Capital XI is deploying capital now. Investments have already been made. Latent Labs, BioCorteX, and Amolyt are among the recipients.
Management Team
Sofinnova's team is experienced. Maina Bhaman is a Partner. Anta Gkelou is a Partner. Karl Naegler is a Partner. Antoine Papiernik chairs the company. Henrijette Richter and Graziano Seghezzi are also Partners.
Global Investor Base
Fund XI gained support globally. Investors came from Europe, North America, Asia, and the Middle East. Many were returning investors. New top-tier investors joined as well.
Leadership Quotes
Antoine Papiernik highlighted the fundraising's importance. He emphasized doubling down on early-stage opportunities. He praised the collaborative, science-driven approach. He is excited to back visionary entrepreneurs. He wants to advance breakthroughs to patients.
Mark Andrews from the British Business Bank commented. He sees Sofinnova as a key life sciences player. Their commitment will boost UK life sciences investment. This will solidify Sofinnova's UK connection.
Christine Hockley addressed the UK market. She emphasized the need for capital. She wants high-potential companies to access funding. Funds with deeper capital pools are needed. They should invest in the UK's growth stage.
Continued Commitment
The fund solidifies Sofinnova's role. They are a cornerstone investor in early-stage ventures. Total capital raised across Sofinnova reached €1.5 billion recently. Fund XI will accelerate scientific advances. It will drive commercial success. This benefits the next generation of healthcare innovators. Sofinnova will continue supporting early-stage biotech and medtech ventures. They will participate in both initial and follow-on rounds.
"